The Second Hospital of Tianjin Medical University
The Second Hospital of Tianjin Medical University
Tianjin, Outside U.S., China3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer | Kidney-sparing; Nab-paclitaxel; PD-1 Inhibitor; Renal Pelvic Carcinoma; Tislelizumab | Recruiting | Phase 2 | 2025-11-18 | NCT07233252 | |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 2 | 2025-08-17 | NCT07126119 | |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, ureter cancer, ureteral disorder, urinary system disorder | Recruiting | Phase 2 | 2025-08-15 | NCT07125547 |